Molecular & Translational Characterisation of IMiD-Mediated BET-Protein Degradation in Multiple Myeloma [ 2017 - 2019 ]

Research Grant

Researchers: A/Pr Jake Shortt (Principal investigator) ,  Prof Andrew Spencer ,  Prof Ricky Johnstone

Brief description Thalidomide-like drugs (called IMiDs) are an essential treatment for multiple myeloma, a common incurable blood cancer. We have discovered that IMiDs destroy proteins that myeloma cells use to ‘read’ cancer-causing genes in their own DNA. We will therefore investigate how important the destruction of these ‘gene readers’ is in myeloma cells, including patient samples. This will set up future studies targeting ‘gene readers’ using IMiDs in combination with other targeted drugs in clinical trials.

Funding Amount $AUD 509,515.07

Funding Scheme Project Grants

Notes Standard Project Grant